David Hoey, CEO, has more than 25 years of executive-level experience in business development, licensing, strategic planning, and financing for technology companies. His experience spans preclinical and clinical development of therapeutics and vaccines, and molecular diagnostic assays and platforms. Mr. Hoey has completed over $425 million in corporate partnering transactions and equity financings in the United States, Europe, and Japan and has secured extensive contracts for government sponsored research. Mr. Hoey is a board member of publicly listed Universal Biosensors Pty. Ltd.